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Abstract
Background: Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the
dystrophin gene. DMD has a complex and as yet incompletely defined molecular pathophysiology hindering
development of effective ameliorative approaches. Transcriptomic studies so far conducted on dystrophic cells and
tissues suffer from non-specific changes and background noise due to heterogeneous comparisons and secondary
pathologies. A study design in which a perfectly matched control cell population is used as reference for
transcriptomic studies will give a much more specific insight into the effects of dystrophin deficiency and DMD
pathophysiology.
Results: Using RNA interference (RNAi) to knock down dystrophin in myotubes from C57BL10 mice, we created a
homogenous model to study the transcriptome of dystrophin-deficient myotubes. We noted significant differences
in the global gene expression pattern between these myotubes and their matched control cultures. In particular,
categorical analyses of the dysregulated genes demonstrated significant enrichment of molecules associated with
the components of muscle cell contractile unit, ion channels, metabolic pathways and kinases. Additionally, some
of the dysregulated genes could potentially explain conditions and endophenotypes associated with dystrophin
deficiency, such as dysregulation of calcium homeostasis (Pvalb and Casq1), or cardiomyopathy (Obscurin, Tcap). In
addition to be validated by qPCR, our data gains another level of validity by affirmatively reproducing several
independent studies conducted previously at genes and/or protein levels in vivo and in vitro.
Conclusion: Our results suggest that in striated muscles, dystrophin is involved in orchestrating proper
development and organization of myofibers as contractile units, depicting a novel pathophysiology for DMD where
the absence of dystrophin results in maldeveloped myofibers prone to physical stress and damage. Therefore, it
becomes apparent that any gene therapy approaches for DMD should target early stages in muscle development
to attain a maximum clinical benefit. With a clear and specific definition of the transcriptome of dystrophin
deficiency, manipulation of identified dysregulated molecules downstream of dystrophin may lead to novel
ameliorative approaches for DMD.
Background
Duchenne Muscular Dystrophy (DMD) is a progressive
and fatal muscle wasting disease, which occurs in 1 of
3500 male births worldwide [1]. DMD and related
animal models such as that of the mdx mouse [2,3] are
caused by mutations in the dystrophin gene that result
in absence of the largest dystrophin isoform (Dp427)
from skeletal, cardiac and smooth muscles, and the CNS
[4,5]. While studies on whole animal and cell culture
models of dystrophin deficiency have allowed significant
progress in unraveling the molecular pathology underly-
ing DMD, the precise pathophysiology remains poorly
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exhibits complex interactions with many other structural
and signalling molecules at the muscle sarcolemma, and
its absence is associated with a diverse range of molecu-
lar and cellular disturbances [8,9]. For instance, along-
side the absence of dystrophin, the stability and cellular
localisation of many other proteins - the so called dys-
trophin associated proteins (DAPs) - are perturbed.
These findings all suggest a complex primary and sec-
ondary pathophysiology associated with dystrophin
deficiency.
Transcriptomic studies of diseased versus normal
muscles could be very informative for understanding
DMD pathophysiology. A number of groups have noted
differences in the gene expression patterns between dys-
trophic muscle tissues of DMD patients and those of
dystrophin-proficient individuals, or mdx compared to
C57BL/6 (normal) mice [10-21]. However, studies of the
direct and primary molecular sequelae of dystrophin
deficiency in intact animals and tissues are complicated
by secondary pathologies resulting from degenerative,
regenerative, fibrotic and inflammatory changes. Cellular
models of dystrophin deficiency can be complicated by
non-clonal comparisons of cell lines, or by hetero-
geneous cellular composition (with variable myoblast,
fibroblast, endothelial cell, and infiltrating blood cell
content) when comparing deficient and control primary
cultures. The optimum cellular model with which to
evaluate the direct and primary molecular events asso-
ciated with dystrophin deficiency involves a system in
which expression of the protein can be manipulated
experimentally in a cell autonomous manner.
RNA interference (RNAi) technology allows expres-
s i o no fas i n g l eg e n et r a n s c r i p ta n dp r o t e i np r o d u c tt o
be efficiently and specifically reduced or knocked down
at the mRNA level [22]. This technique provides the
opportunity to study these effects under controllable
conditions, and is especially useful for multifunctional
proteins such as dystrophin.
Here, we describe the specific and immediate effect of
dystrophin deficiency on global gene transcription in
primary muscle cell cultures in which dystrophin had
efficiently been knocked down by RNAi. This approach
provided the opportunity to compare the transcriptomes
in dystrophin-deficient primary myotube cultures to that
of their corresponding clonal cell populations, avoiding
the heterogeneity routinely associated with primary cell
cultures and tissue biopsies. Our results suggest that in
striated myofibers, dystrophin is mainly required for
proper development and organization of the contractile
unit, implicating a novel pathophysiology for DMD.
Genes associated with ion channels, metabolic pathways
and kinases were also dysregulated in response to dys-
trophin deficiency. Abnormal expression of certain
genes detected in our model could potentially explain
conditions and endophenotypes associated with dystro-
phin deficiency, such as dysregulation of calcium
homeostasis or cardiomyopathy.
Results
Transcriptome of dystrophin-deficient myotubes
We previously reported potent and specific knockdown
of dystrophin using four different small interferring
RNAs (siRNAs) [23]. Here, we used the most effective
siRNA (referred to as D2) to knock down dystrophin in
myotubes prepared from C57BL10 mice limb muscles.
Briefly, siRNA transfections were performed at 100 nM
on days two and four post-seeding and cells were col-
lected on day six post-seeding, forty-eight hours after
induction of differentiation (see Materials & Methods
for further details). Figure 1 shows a western blot analy-
sis of dystrophin expression in myotubes used for tran-
scriptomic studies. This experiment showed close to
zero expression of dystrophin in myotubes treated with
the D2 siRNA, while this protein was well expressed
both in myotubes treated with an siRNA targeting firefly
GL2 luciferase (treatment control) and in untreated
myotubes. No detectable change in myotube morpho-
logy was observed under phase-contrast microscopy, but
immunostaining revealed an almost complete lack of
dystrophin in D2 siRNA-treated myotubes (data not
shown). In order to perform the transcriptomic analysis,
we generated 7 biological replicates of primary myo-
blasts treated with the siRNA targeting dystrophin (D2),
7 biological replicates of primary myoblasts treated with
the siRNA targeting luciferase (GL2, as treatment con-
trols), and 4 replicates of untreated primary myoblasts
(Untr.). The biological replicates were prepared and pro-
cessed on 4 separate occasions, hence acting as indepen-
dent replicates, too.
We used Illumina gene expression arrays (Mouse
whole genome-6 v1.1) to evaluate the myotubes under
investigation, and analysed the data to determine the
Figure 1 Western blot showing strong dystrophin (Dp427)
downregulation in myotubes treated with siRNA targeting
dystrophin (D2). The samples were obtained directly from those
used for gene expression arrays. Untr.: Untreated myotubes. GL2:
Myotubes treated with siRNA targeting firefly luciferase. D2:
Myotubes treated with an optimal siRNA targeting dystrophin
(referred to as D2 in a previous study [23]). mdx: Myotubes
prepared from muscles from mdx mice. Nedd-4: loading control.
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for details). We made two statistical comparisons: 1)
global gene expression in myotubes knocked down for
dystrophin compared to the untreated myotubes (list 1);
and 2) global gene expression in firefly GL2 siRNA-trea-
ted myotubes compared to the untreated myotubes
(list 2). By removing from list 1 the genes in common
between lists 1 and 2, we created a main list of genes
changed specifically by dystrophin knockdown (Addi-
t i o n a lf i l e1 ) .T h e nw em a d eaf inal list of dysregulated
genes by compiling those from the main list that chan-
ged by more than 1.5 fold (with an adjusted (Benjamini-
Hochberg multiple testing corrected) p values less than
0.05) (Additional file 2), and those that changed in both
comparisons but in different directions (Additional file
2, italics; see Additional file 3 for all genes common to
list 1 and 2). To confirm the array data, we performed
RT-qPCR on six of the dysregulated genes. As demon-
strated in Figure 2, RT-qPCR confirmed gene expression
changes and corroborated the array data.
Many genes of interest with respect to skeletal mus-
cle function or the DMD phenotype can be identified
amongst the dysregulated genes displayed in Addi-
tional file 2. At first glance, several genes that have
been associated with various myopathies are recog-
nised amongst the differentially regulated genes. These
include kyphoscoliosis peptidase (Ky) [24], cofilin 2
(Cfl2) [25,26], calpain 3 (Capn3) [27], titin-cap (Tcap)
[28,29] and phosphofructokinase (Pfkm) [30-32] (see
Table 1 for all genes from Additional file 2 cited in
the text).
With respect to the significance of change, dystrophin
transcript is positioned to the top of the list of signifi-
cantly changing genes, only next to ribosomal protein
L3-like (Rpl3l). ‘CAP-GLY domain-containing linker
protein family, member 4’ (Clip4)a n dP a r v a l b u m i n
(Pvalb) are two other transcripts with associated
p values similar to that of dystrophin transcript.
Ion channels [33], metabolic pathways [34-37] and
kinases-related signaling pathways [38-40] are affected
in dystrophin-deficient muscle cells. Several genes of
each group were dysregulated in dystrophin-deficient
myotubes in our experiment. For ion channels, Scn1b is
downregulated both as reported by Pescatori et. al. [14]
and in our experiments. Pescatori et. al. used muscles
from children affected with DMD under the age of 2 -
before any overt skeletal muscle pathology - when one
would expect to see a transcriptome related to dystro-
phin deficiency without secondary complications.
Among metabolism associated molecules, ‘muscle glyco-
gen phosphorylase’ (Pygm), ‘phosphorylase kinase
gamma 1’ (Phkg1), ‘phosphofructokinase, muscle’ (Pfkm),
‘glycerol-3-phosphate dehydrogenase 1’ (Gpd1)w e r e
reproducibly downregulated in our experiment and as
reported by the aforementioned group [14]. Further,
despite different species being studied, we found com-
parable results for ‘cholinergic receptor, nicotinic, epsi-
lon polypeptide’ (Chrne), ‘cylin-dependent kinase
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Figure 2 RT-qPCR experiment supporting expression array data. For RT-qPCR, the cDNAs made using 4 untreated biological replicates were
pooled in equal amounts and used in triplicate per experiment as a reference. For each of the treatments (dystrophin knockdown (KD) or GL2
siRNA), the biological replicates from two treatment occasions (two biological replicates per each treatment occasion) were used. For each
treatment occasion, the cDNAs from each biological replicate were mixed in equal amounts and used in triplicate. Relative gene expression was
calculated by the ΔΔCT method. Y axis: the normalised ratio (fold change) of expression between the treated samples (Dystrophin KD or GL2
siRNA control) versus untreated samples. Error bars indicate mean +/- 1 SD.
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Page 3 of 12inhibitor 1A’ (Cdkn1a), calpain 3 (Capn3), lipin1 (Lpin1)
and ‘monoamine oxidase B’ (Maob).
Transcripts of several kinases were dysregulated in our
model; amongst them, ‘mitogen-activated protein kinase
kinase kinase 7’ (Map3k7), ‘mitogen-activated protein
kinase kinase kinase 9’ (Map3k9) and ‘phosphatidylinosi-
tol 3-kinase, catalytic, beta polypeptide’ (Pik3cb)a n d
‘AP2-associated kinase 1 (Aak1)’ all upregulated. Simi-
larly, PI3K/Akt pathway is reported to be activated in
pre-necrotic (<2 weeks) diaphragm and in myotubes
from mdx mice [38]
Heart and brain are affected in DMD, in addition to
skeletal muscles. There are several genes identified in our
experiment that could potentially participate in the devel-
opment of heart and brain associated endophenotypes in
DMD. These genes include ‘Beta myosin heavy chain’
(Myh7), Obscurin (Obscn), ‘heat shock protein, alpha-
crystalline-related B6’ (Hspb6), titin (Ttn), titin-cap
(Tcap), and myospryn (Cmya5) for heart associated phe-
notypes, and ‘Cytoplasmic fragile X mental retardation
(Fmr1) interacting protein 2’ (Cyfip2), ‘gamma-amino-
butyric acid A receptor, delta’ (Gabrd), and ‘sodium
channel, voltage-gated, type I, beta’ (Scn1b)( T a b l e1 )f o r
brain associated phenotypes.
Gene Ontology and Ingenuity pathway analyses
In order to have a systematic view on gene categories
altered by dystrophin deficiency, we used the tool provided
by the Database for Annotation, Visualisation and Inte-
grated Discovery (DAVID) [41,42] to conduct Gene
Table 1 Gene differentially regulated by dystrophin deficiency and cited in the text
Entrez ID Gene Symbol Gene Name Fold Change Adjusted p value
66211 Rpl3l ribosomal protein l3-like -6.3 3.80E-08
13405 Dmd dystrophin, muscular dystrophy -3.7 9.54E-08
19293 Pvalb parvalbumin -6.1 9.54E-08
78785 Clip4 CAP-GLY domain containing linker protein family, member 4 -3 9.54E-08
16716 Ky kyphoscoliosis peptidase -4.1 1.48E-07
59011 Myoz1 myozenin 1 -3.6 2.46E-07
19130 Prox1 prospero-related homeobox 1 3 2.55E-05
233199 Mybpc2 myosin binding protein c, fast-type -2.3 3.81E-05
12335 Capn3 calpain 3 -2.1 3.82E-05
18682 Phkg1 phosphorylase kinase gamma 1 -3.9 3.82E-05
14403 Gabrd gamma-aminobutyric acid (gaba-a) receptor, subunit delta -4.2 8.94E-05
243912 Hspb6 heat shock protein, alpha-crystallin-related, b6 -1.9 1.77E-04
140781 Myh7 myosin, heavy polypeptide 7, cardiac muscle 2.7 2.10E-04
21393 Tcap titin-cap -1.7 2.45E-04
76469 Cmya5 cardiomyopathy associated 5 -1.8 2.74E-04
380698 Obscn obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF -2 3.19E-04
76884 Cyfip2 riken cdna 1500004i01 gene -2.1 4.12E-04
12632 Cfl2 cofilin 2, muscle -1.7 8.51E-04
100072 Camta1 calmodulin binding transcription activator 1 -1.6 8.96E-04
20266 Scn1b sodium channel, voltage-gated, type i, beta -1.7 9.09E-04
18642 Pfkm phosphofructokinase, muscle -1.5 1.10E-03
11448 Chrne cholinergic receptor, nicotinic, epsilon polypeptide -3.4 1.16E-03
74769 Pik3cb phosphatidylinositol 3-kinase, catalytic, beta polypeptide 1.5 1.25E-03
12372 Casq1 calsequestrin 1 -1.6 3.27E-03
14245 Lpin1 lipin 1 -1.5 3.79E-03
109731 Maob monoamine oxidase b -1.5 4.95E-03
12575 Cdkn1a cyclin-dependent kinase inhibitor 1a (p21) -1.5 6.65E-03
14555 Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble) -1.7 6.65E-03
19309 Pygm muscle glycogen phosphorylase -1.6 7.55E-03
26409 Map3k7 mitogen activated protein kinase kinase kinase 7 (Synonym Tak1) 1.5 1.22E-02
338372 Map3k9 mitogen-activated protein kinase kinase kinase 9 1.8 1.66E-02
11474 Actn3 actinin alpha 3 -1.6 1.75E-02
20661 Sort1 sortilin 1 1.6 1.82E-02
This table details genes from Additional file 2 that were cited in the text. Table sorted by ascending adjusted p values. Italicized genes are those dysregulated in
dystrophin siRNA treated samples versus untreated samples, but changing in the opposite direction in the GL2 siRNA treated versus untreated samples (see
result section for details).
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file 2. As demonstrated in Table 2, a stringent approach to
considering overrepresented GO terms (>2 fold enrichment
with adjusted p values < 0.1) indicated enrichment for genes
involved in muscle contraction, such as those contributing
to sarcomere and ion channels structures. Furthermore, a
less stringent but still significant (p < 0.05) approach
revealed overrepresentation of molecules involved in meta-
bolic pathways and kinases (Additional file 4).
We used Ingenuity Pathway Analysis (IPA) (Ingenuity®
Systems, http://www.ingenuity.com) to further investi-
gate the networks and functions possibly affected in dys-
trophic muscles. Among the genes in Additional file 2,
IPA identified 229 network-eligible genes and suggested
14 main gene networks as being dysregulated by
dystrophin deficiency (Additional file 5). Moreover, IPA
discovered very significant enrichment (adjusted p
value = 0.0006) of molecules involved in muscle con-
traction as well as significant enrichment (adjusted p
value < 0.05) of other molecules involved in muscle
(skeletal and cardiac) functions and disorders, metabo-
lism of carbohydrates and neurological disorders
amongst differentially expressed genes in our model
(Table 3). IPA also indicated enrichment (adjusted p
value < 0.05) of genes involved in actin cytoskeletal and
calcium signaling canonical pathways (Table 4).
miRNAs at the dysregulated genes loci
To evaluate possible indirect microRNA (miRNA) dys-
regulation by dystrophin deficiency, we investigated the
Table 2 Gene ontology (GO) analysis of differentially expressed genes listed in the Additional file 2
Category Term Genes FE p val. Adj. p
val.
Cellular
Component
GO:0044449 contractile
fiber part
OBSCN, DMN, DMD, MYBPC2, TCAP, MYH13, MYH1, LDB3, ACTN3, MYBPC3, MYH7,
PYGM, MYH4, TPM3,
13.83 1.74E-11 6.77E-09
Cellular
Component
GO:0030017 sarcomere OBSCN, DMN, DMD, MYBPC2, TCAP, MYH13, MYH1, LDB3, ACTN3, MYBPC3, MYH7,
PYGM, MYH4, TPM3,
14.25 1.16E-11 9.06E-09
Cellular
Component
GO:0030016 myofibril OBSCN, DMN, DMD, MYBPC2, TCAP, MYH13, MYH1, LDB3, ACTN3, MYBPC3, MYH7,
PYGM, MYH4, TPM3,
12.89 4.47E-11 1.16E-08
Cellular
Component
GO:0043292 contractile
fiber
OBSCN, DMN, DMD, MYBPC2, TCAP, MYH13, MYH1, LDB3, ACTN3, MYBPC3, MYH7,
PYGM, MYH4, TPM3,
12.38 7.61E-11 1.48E-08
Cellular
Component
GO:0005863 striated
muscle thick filament
MYH7, OBSCN, MYH4, MYBPC2, MYH13, MYH1, MYBPC3, 36.18 1.55E-08 2.01E-06
Cellular
Component
GO:0032982 myosin
filament
MYH7, OBSCN, MYH4, MYBPC2, MYH13, MYH1, MYBPC3, 36.18 1.55E-08 2.01E-06
Cellular
Component
GO:0005859 muscle
myosin complex
MYH7, OBSCN, MYH4, MYBPC2, MYH13, MYH1, MYBPC3, 33.60 2.67E-08 2.98E-06
Cellular
Component
GO:0016460 myosin II
complex
MYH7, OBSCN, MYH4, MYBPC2, MYH13, MYH1, MYBPC3, 29.40 6.95E-08 6.78E-06
Molecular
Function
GO:0008092
cytoskeletal protein
binding
OBSCN, DMD, MYBPC2, MYH13, MYH1, ACTN3, EPB4.1L4B, MYBPC3, DCX, MTAP7,
MYH7, MYH4, MYOZ1, TMOD4, PACSIN1, PSTPIP2, TPM3, SCIN, CFL2, SPNB1,
3.79 1.37E-06 3.63E-03
Cellular
Component
GO:0030018 Z disc DMN, OBSCN, PYGM, DMD, TCAP, LDB3, 13.44 7.16E-05 5.57E-03
Cellular
Component
GO:0031674 I band DMN, OBSCN, PYGM, DMD, TCAP, LDB3, 11.52 1.54E-04 1.08E-02
Cellular
Component
GO:0005856
cytoskeleton
DMN, OBSCN, TTL, MYBPC2, MYH13, MYH1, ABI2, ACTN3, EPB4.1L4B, MTAP7, KRT18,
TMOD4, PSTPIP2, CFL2, TPM3, DYNLRB2, GAN, DMD, LDB3, MYBPC3, DCX, MYH7,
SGCG, KY, MYH4, MYOZ1, SCIN, SPNB1,
2.16 2.14E-04 1.27E-02
Cellular
Component
GO:0016459 myosin
complex
MYH7, OBSCN, MYH4, MYBPC2, MYH13, MYH1, MYBPC3, 8.11 2.09E-04 1.35E-02
Biological
Process
GO:0003012 muscle
system process
MYH7, MYH4, MYBPC2, CASQ1, KCNMA1, MYH13, MYH1, TPM3, ACTN3, MYBPC3, 7.63 5.92E-06 1.51E-02
Biological
Process
GO:0006936 muscle
contraction
MYH7, MYH4, MYBPC2, CASQ1, KCNMA1, MYH13, MYH1, TPM3, ACTN3, MYBPC3, 7.63 5.92E-06 1.51E-02
Molecular
Function
GO:0031420 alkali
metal ion binding
KCNC1, KCNA7, SCN3B, SCN1B, TTL, SLC9A7, ATP1B2, IMPA2, KCNMA1, KCNK3,
SLC24A5, GMPR,
4.82 3.95E-05 5.10E-02
Molecular
Function
GO:0030955 potassium
ion binding
KCNC1, KCNA7, TTL, SLC9A7, ATP1B2, KCNMA1, KCNK3, SLC24A5, GMPR, 6.08 1.13E-04 7.22E-02
Molecular
Function
GO:0003779 actin
binding
DMD, MYBPC2, MYH13, MYH1, ACTN3, MYBPC3, MYH7, MYH4, TMOD4, PSTPIP2,
TPM3, SCIN, CFL2, SPNB1,
3.77 8.93E-05 7.59E-02
DAVID tool was used for this analysis. Only terms with Benjamini-Hochberg adjusted p values < 0.1 and Fold Enrichment (FE) greater than 2 are displayed. Table
sorted by ascending adjusted p values.
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of the genes displayed in Additional file 2. Table 5
details the miRNAs identified to happen at the dysregu-
lated genes loci. miRbase miRNA data base (Sanger
Inst., UK [43]) Release 12 was used for this analysis.
Discussion
Despite much effort toward disentangling the molecu-
lar basis of DMD pathophysiology, it remains unclear
how the absence of one molecule results in a compli-
cated phenotype such as DMD. This is partly due to
the complexity of dystrophin interactions in muscle
cells. As shown by others and in the present work, the
absence of dystrophin starts a cascade of derangements
in several networks. This results in underdeveloped
muscles, prone to the adverse effects of physical stres-
ses that add another level of molecular complexity to
the disorder. To capture the most direct effect of
Table 3 Top functions and disorders predicted by IPA to be affected by dystrophin deficiency
Function or Disorder Molecules Adjusted p
value
contraction of muscle ACTN3, CASQ1, CHRNE, CKMT2, EGF, GJA5, HSPB6, KCNMA1, MYBPC1, MYBPC2, MYBPC3, MYH1, MYH7,
MYLK2, TMOD4
6.33E-04
atrophy of muscle cells ACHE, FBXO32, PPARGC1A 1.27E-02
skeletal and muscular
disorder
ACHE, ACTN3, AIG1, ALKBH8, ARPP-21, BAALC, BLNK, CACNA2D1, CAMK2B, CAMTA1, CAPN3, CASQ1,
CDC42BPA, CDH13, CDKN1A, CENPM, CFL2, CHRNE, CLIP4, COL23A1, CYFIP2, DCLK3, DMD, DNAJB6, GABRD,
GAN, GIGYF2, GPD1, HTR2B, IL12A, IMPA2, IP6K3, KCNC1, KCNMA1, KCNN3, LDB3, LPIN1, MAOB, MLF1,
MLLT3, MYBPC1, MYH7, MYH8, MYT1L, NDRG2, NOG, PADI2, PFKM, PKD1L1, PPARGC1A, PVALB, RCSD1,
SCN1B, SCN3B, SERPINB1, SGCG, SORT1, SPTB, STARD10, TBC1D4, TCAP, TNRC6B, TP53BP1, TPM3, UCK2,
WBSCR17, WFDC1, XK
1.46E-02
cardiovascular disorder ABI2, ACHE, ACTN3, ARHGAP20, BLNK, CACNA2D1, CAMK2B, CAMTA1, CDC42BPA, CDH13, CDKN1A,
CHRNA10, CHRNE, COL23A1, CSRNP3, CYFIP2, DMD, ENTPD3, FAM65B, GABRD, GAN, GJA5, GRHL1, HERC1,
HSD11B1, HTR2B, IL12A, IMPA2, KCNA7, KCNC1, KCNK3, KCNMA1, KCNN3, KIAA1409, MALL (includes
EG:7851), MAOB, MLF1, MSI2, MYBPC1, MYBPC3, MYH7, MYH8, MYLK2, NPPB, PPARGC1A, PSTPIP2, PTPRO,
RCSD1, SCN1B, SGCG, SLC46A3, SLC9A2, SPTB, TBC1D4, TCAP, TNRC6B, WBSCR17, XK
2.07E-02
cardiomyopathy GJA5, HTR2B, MYBPC3, MYH7, MYLK2, NPPB, PPARGC1A, SGCG, TCAP 2.07E-02
variant angina CACNA2D1, RCSD1, SGCG 2.07E-02
Huntington’s disease ACTN3, AIG1, ARPP-21, CAMK2B, CASQ1, CYFIP2 (includes EG:26999), GABRD, GPD1, KCNN3, MAOB, MLF1,
MYH7, MYT1L, PFKM, PPARGC1A, PVALB, SCN1B, SCN3B, SORT1, STARD10, TPM3, UCK2
3.09E-02
disease of muscle CHRNE, FBXO32, MYH1, MYH4, PPARGC1A, SGCG, TPM3 4.23E-02
fatigue ACHE, CHRNE, PPARGC1A, SCN1B 4.23E-02
developmental disorder
of muscle
FBXO32, MYH1, MYH4, SGCG, TPM3 4.39E-02
pervasive developmental
disorders
ACHE, CHRNA10, CHRNE, GABRD, HTR2B, SCN1B, SCN3B 4.39E-02
deformation of nucleus CDKN1A, MAP7 4.39E-02
metabolism of
carbohydrate
CMAH, GPD1, IMPA2, IP6K3, NISCH, PDK4, PFKM, PHKG1, PPARGC1A, PPP1R3C, PYGM, SGSH, SOCS4,
ST3GAL6
4.39E-02
morphogenesis of
cardiac muscle
MYBPC3, MYH7, MYLK2, TCAP 4.63E-02
muscular dystrophy CAPN3, DMD, MYH7, SGCG, TCAP 4.69E-02
neurological disorder ACHE, ACTN3, AIG1, ALKBH8, ARPP-21, BAALC, BLNK, CACNA2D1, CAMK2B, CAMTA1, CAPN3, CASQ1,
CATSPER4, CDC42BPA, CDH13, CHRNA10, CHRNE, CLIP4, CNKSR1, COL23A1, CYFIP2, DFNA5, DMD, DNAJB6,
DNAJC5, EGF, EYA3, FZD3, GABRD, GAN, GDAP1, GIGYF2, GPD1, HTR2B, IGFN1, IL12A, IMPA2, KCNC1,
KCNMA1, KCNN3, KIAA1409, KPNA6, LRCH1, MAOB, MLF1, MLLT3, MSI2, MT3, MYH7, MYH8, MYT1L, NDRG2,
OPN3, P2RY2, PADI2, PFKM, PKD1L1, PLA2G4E, PPARGC1A, PPP1R14C, PVALB, SCN1B, SCN3B, SERPINB1,
SGCG, SORT1, SPTB, STARD10, SUSD4, TMEM108, TPM3, TTC7B, TTLL7, UCK2, WBSCR17, WWC1, XK
4.80E-02
developmental process
of muscle
ACHE, CAPN3, CDKN1A, DMD, KY, MYBPC3, MYH7, MYLK2, MYOZ1, PDK4, SGCG, TCAP 4.80E-02
Genes listed in the Additional file 2 were used for this analysis. Only functions and disorders with Benjamini-Hochberg corrected p values < 0.05 are displayed.
Table 4 Top predicted (by IPA) canonical pathways to be affected in dystrophin-deficient muscle cells
Canonical Pathways Molecules Adj p value
Actin Cytoskeleton Signaling MYH4, ABI2, CYFIP2, MYH8, CFL2, MYLK2, EGF, PIK3CB, MYH7, ACTN3, MYH1 2.45E-02
Calcium Signaling MYH4, TPM3, MYH8, CASQ1, CHRNE, MYH7, CHRNA10, CAMK2B, MYH1 3.390E-02
Only Pathways with Benjamini-Hochberg corrected p values under 0.05 are displayed.
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ble to the early myogenesis stages when dystrophin
naturally starts to be expressed. Having this in mind,
we decided to use primary muscle cultures to study
early myogenesis in the absence of dystrophin, by com-
paring the transcriptome of dystrophin-deficient cells
to that of their normal counterparts shortly after
induction of myogenesis. Similar approaches have been
taken by others; however, we designed this experiment
to avoid the cellular heterogeneity associated with the
other studies. Accordingly, we used RNAi to knock
down dystrophin in mouse primary myotubes, and
compared transcriptomes in these cells to those in the
same cell population but in which dystrophin had not
been targeted. We have previously shown that RNAi is
a robust technique for dystrophin knockdown [23].
Here, applying dystrophin RNAi to samples used for
our transcriptomic studies resulted in close to zero
dystrophin expression (Figure 1). We decided to ana-
lyze samples collected 48 hours after differentiation. At
that time point, we did not observe any detectable
change in myotube morphology or timing of fusion.
We selected this early time point in order to focus on
the early myogenesis events in the presence and
absence of dystrophin expression, but avoid any unre-
lated secondary events such as myotube rupture and
culture senescence. To account for possible unrelated
variations, the experiment involved biological replicates
prepared on four occasions (see Materials & Methods
section). This design produced meaningful results, cap-
able of giving mechanistic insights into the conditions
and endophenotypes associated with DMD.
A systematic overview of genes listed in Additional file
2 by GO and IPA analyses indicated significant overre-
presentation of genes associated with the physiology of
contraction, kinases, or metabolic pathways. This indi-
cates that dystrophin is not just a molecule providing
structural support to myofibers, but its presence is cru-
cial for proper development and function of striated
muscle as a contractile unit.
Other earlier studies on dystrophin deficiency support
our observation that ion channels [33], kinases [38-40]
and metabolic pathways [34-37] are also affected in
dystrophic muscles. Here, we provide a more compre-
hensive view of the genes dysregulated under these cate-
gories and indicate future lines of researches to address
these pathways.
Dysregulated genes involved in development of skeletal
muscle phenotype
Clip4 and Pvalb had associated p values similar to that
of dystrophin transcript. Though not much is known
about Clip4 function, Pvalb is reported to be downregu-
lated in DMD [44] and mdx [45] muscles. PVALB binds
to Ca
2+ and its calcium buffering capacity is important
for calcium homeostasis during muscle contraction
when high level of calcium is released into the sarco-
plasm. Dysregulation of calcium homeostasis, with
increased intracellular [Ca
2+]i is well documented in
dystrophic muscles [46]. In line with this, Calsequestrin
1( Casq1), the gene for CASQ1 calcium-binding protein
located in sarcoplasmic reticulum (SR), was also down-
regulated in our model of dystrophin deficiency. Sup-
portively, DMD muscles are reported to have
deficiencies in this protein [47,48]. CASQ1 is believed to
be essential for the normal development of the SR, and
for calcium storage and regulation inside SR [49].
Kinases can initiate long range signaling activity by
activating transcription factors that in turn will activate
transcription of their target genes. One way for kinases
to specify their local activity is by being targeted and
anchored to the region where their activity is required
[50]. A single molecule such as dystrophin could regu-
late the expression of a variety of myogenesis-related
genes through its role in anchoring other molecules in
the right locale. This property can help localise kinases
and/or other signaling molecules to where their func-
tions are required for proper myogenesis. For instance,
dystrobrevin [51] and synemin [52], two dystrophin
associated proteins [53,54], act to localise protein kinase
A( P K A ) .M y o s p r y n( Cmya5), a gene downregulated in
dystrophin-deficient myotubes in our model, has binding
sites for PKA, anchoring it at the costamere to localise
PKA signaling at this complex region [55]. Supportively,
it has been documented that dystrophin deficiency
results in downregulation [19,40] and mislocalisation of
myospryn in skeletal muscles, resulting in lower PKA
activity [40]. Nearly two thirds of the genes dysregulated
in our experiments were downregulated (220 of 333,
Additional file 2) indicating possible under-activity of
certain myogensis-related transcription factors normally
activated by kinases. In fact, dysregulation of some tran-
scription factors in mdx skeletal muscle has already
been reported [56].
Our results also suggest that myofiber type fate deter-
mination may be affected by dystrophin deficiency.
Upregulation of ‘prospero-related homeobox 1’ (Prox1)
Table 5 Genes from Additional file 2 with miRNA loci at
their intronic regions
Gene miRNA
Arpp21 mmu-miR-128-2
Dusp19 mmu-miR-684-1
Klf9 mmu-miR-1192
Myh7 mmu-miR-208b
R3hdm1 mmu-miR-128-1
miRbase miRNA database, Release 12 was used for this analysis.
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Our samples in which dystrophin had been downregu-
lated showed three-fold increase in Prox1. Additionally,
‘Fast type myosin binding protein c’ (Mybpc2)a n d
‘alpha actinin3’ (Actn3) were downregulated in dystro-
phin deficient myotubes in our experiment. Actn3 levels
increase in accord with increases in skeletal muscle fast
fibers [58]; and specific expression of Mybpc2 in fast
fibre muscles has also been documented [59].
Dysregulated genes involved in development of heart
phenotype
Heart is another organ which is involved by the patho-
genesis of dystrophin deficiency. There are several mole-
cules identified by our model that can potentially
explain the mechanism(s) by which heart is adversely
affected in DMD. For instance, obscurin, which was
downregulated in our experiment, is required for proper
assembly of M-band and A-band and myofibrillar clus-
ters and for the regular alignment of the SR network
around the contractile apparatus [60,61]. Hspb6,w h i c h
associates with actin, is a cardioprotector under stressful
conditions [62] and its mRNA was downregulated in
association with dystrophin deficiency in this
experiment.
Z-disc and costamere and their associated molecules
function as mechanosensors in striated muscles, and
their perturbation can result in architectural distortion
of the affected muscle cells [63]. Hence, mutations in
some genes involved in this area, such as titin and titin-
cap, can result in cardiomyopathy [64,65]. Titin-cap was
downregulated in dystrophin-deficient myotubes in our
experiment, as was myozenin 1, another Z-disc asso-
ciated protein.
Expression of the myospryn gene was downregulated
by dystrophin deficiency in our model. It is also downre-
gulated in both DMD [19] and mdx [40]; and single
nucleotide polymorphisms at the myospryn locus are
associated with ventricular hypertrophy [66]. This gene
is expressed exclusively in heart and skeletal muscle
during embryogenesis and in adult striated muscle [67].
Interestingly, as it was mentioned earlier myospryn pro-
tein is a docking molecule for protein kinase A at the
costamere, and involved in localising and specifying
signal transduction at this region [40].
Conclusion
Our work depicts a specific transcriptome associated
with dystrophin deficiency, with minimal noise from
non-specific complications such as non-clonal cells or
biopsy-associated issues such as necrosis/degeneration/
regeneration. While our results are affirmatively reprodu-
cing several previous in vitro and in vivo experiments,
indicating the soundness of the data, they additionally
suggest that dystrophin may be crucial for proper devel-
opment of striated muscles as an organized contractile
unit, implicating a novel pathophysiology for DMD. Dys-
regulation of several molecules converging at functions
associated with the contractile unit of the myofibers is
indicative of an aberrant myogenesis process resulting in
maldeveloped myofibers which may be susceptible to
physical or cytotoxic stress. Future experiments should
include time course studies to identify longer-term
sequelae of dystrophin deficiency. These data comple-
ment our previous in vivo work with dystrophin shRNAs
expressed from AAV vectors [23], which suggested that
the presence of dystrophin is not as essential after
striated muscles have fully developed. Accordingly, tran-
sient gene therapy or other approaches to counter dystro-
phin-deficiency at early stages of skeletal muscle
maturation might confer long lasting therapeutic benefit.
In addition, the identification of dysregulated genes
linked to dystrophin deficiency will provide insights and
experimental approaches to define novel therapeutic
targets for the potential treatment of DMD.
Methods
Cell culture & siRNA transfection
Primary muscle cultures were prepared from limb mus-
cles of 3 to 5 day old mice, as described previously [68].
Seven biological replicates of primary myoblasts treated
with the siRNA targeting dystrophin, or the siRNA tar-
geting GL2 luciferase (as treatment controls), and 4
replicates of untreated primary myoblasts were prepared
on four occasions. In order to have a uniform cell popu-
lation between replicates at each instance, the muscle
cell homogenates from different mice were mixed well
and the resulting cell mixture was used to prepare the
cultures. The cells were seeded in 150 cm
2 tissue culture
plates and one animal per plate was used. After approxi-
mately 48 hours, the cultures were about 60% confluent
and were subjected to the first transfection with siRNAs.
The siRNA targeting dystrophin had been designed
using an algorithm developed by Cenix BioScience
GmbH (Dresden, Germany) and manufactured by
Ambion (Austin, USA) (see [23] for more details). The
control siRNA targeting firefly GL2 luciferase was
ordered from Dharmacon (Lafayette, USA). siRNAs
were introduced into the primary muscle cultures at a
final concentration of 100 nM using Oligofectamine
transfection reagent (Invitrogen, Paisley, UK), following
the manufacturer’s instructions. Briefly, at the time of
transfection, media were replaced with 13.5 ml per plate
of complete DMEM supplemented with 10% serum. To
transfect the cells in each plate 45 μl oligofectamine was
gently diluted in 105 μl OptiMEM (Invitrogen) and
incubated at room temperature for 10 minutes. The
oligofectamine preparation was then added to 75 μl
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OpiMEM, mixed gently and incubated for 20 minutes at
room temperature before adding to the plates. 7 hours
after transfection 15 ml of complete DMEM supplemen-
ted with 20% serum was added to each plate. 96 hours
after seeding, when cultures were fully confluent, media
were changed to serum-free Dulbecco’s Minimal Essen-
tial Medium (DMEM) to induce differentiation of myo-
blasts, and a second transfection was performed at this
time in serum free media as explained above. Cells were
harvested for protein and total RNA assays 48 hours
after the second transfection.
RNA isolation
Total RNA was extracted using PARIS kit (Ambion)
according to the manufacturer recommended protocol.
The quality of RNAs was checked using Agilent Bioana-
lyser (Santa Clara, USA). RNAs were stored at -80°C
until used.
Antibodies
We used the following antibodies in this experiment:
mouse monoclonal antibody NCL-DYS2 detecting the
C-terminus of dystrophin (Clone Dy8/6C5; Novocastra
L a b o r a t o r i e s ,U K ) ,N e d d - 4m ouse monoclonal antibody
detecting Nedd-4 (Transduction Laboratories, USA) and
Goat anti-mouse HRP-secondary antibody (Jackson
ImmunoResearch Laboratories, USA).
Western Blotting
Protein extracts were obtained by using a small portion
of the same cell samples lysed for RNA isolation using a
PARIS kit (Ambion) as instructed by the manual. The
cell lysates were added with equal volumes of 2× lysis
buffer. 1× lysis buffer contained 75 mM Tris-HCl
(Sigma-Aldrich, UK) pH 6.8; 10% SDS (Sigma-Aldrich);
20% Glycerol (Sigma-Aldrich); 200 mg/ml EDTA
(Sigma-Aldrich) and 20 μg/ml phenylmethylsulfonyl
fluoride (Sigma-Aldrich). Cell lystes were then passed
through a 25 gauge hypodermic needle several times to
shear DNA and hence reduce viscosity. DTT (Dithio-
threitol, Sigma-Aldrich) and bromophenol blue were
excluded from the buffer in this stage as they interfered
with protein assay. To determine the total protein
amount in samples, the BCA protein assay kit and pro-
tocol (Perbio Science, UK) was used. Twenty micro-
grams of each of the samples was run on Tris-Acetate
3-8% NuPAGE gels (Invitrogen) using Tris-acetate SDS
running buffer (Invitrogen) for dystrophin detection.
RNA amplification and Illumina expression array chip
hybridisation
The RNA amplification, chip hybridization and data
e x t r a c t i o nw a sd o n ea sas e r v i c eb yT h eC e n t r ef o r
Applied Genomics, Toronto, Canada. Illumina Mou-
seWG-6_V1_1 gene expression arrays (San Diego, USA)
were used for global gene expression studies. 250 ng
total RNA was used to make amplified cRNAs using
Illumina TotalPrep RNA amplification kit (Ambion).
1.5 μg cRNA was then hybridized to each microarray
chip following manufacturer instructions. The signals
were detected and gathered using BeadArray Reader
(Illumina). The data were then uploaded to Bead Studio
software (Illumina) and after qualitative evaluation, the
text file data were extracted and statistically analyzed as
explained below. Gene expression data have been depos-
ited in Gene Expression Omnibus (GEO) http://www.
ncbi.nlm.nih.gov/geo/index.cgi with the assigned GEO
accession number GSE20548.
Statistical analysis
Background correction was made as described by Iri-
zarry et al. [69]. The background corrected data were
then transformed into log2 scales, and quantile normali-
sation was performed between arrays as previously
described [70]. The three-step normalisation procedure
was carried out using the Lumi software package for the
R programming environment [71]. To assess differential
gene expression, LIMMA (linear models for microarray
data) method [72] was used. p values were adjusted for
multiple testing using the Benjamini and Hochberg
method.
RT-qPCR and primers
RNA samples were first treated with DNase I (Qiagen,
Germany) as instructed by the manufacturer to remove
possible DNA contaminations. 1 μg total RNA was then
reverse transcribed using the Supercript III reverse tran-
scription kit (Invitrogen) following manufacturer
instructions. 1-2 ul of 1:5 diluted cDNA were used for
quantitative PCR reaction using Brilliant II fast SYBR
Green qPCR master mix (Agilent Technologies) in a
total of 15 μL reaction volume. PCR reaction was
carried out as follows: 10 minutes at 95°C followed by
40 cycles at 95°C for 20 s and 60°C for 60 s. Specificity
of the PCR product was checked by melting-curve ana-
lysis using the following program: 55°C increasing 0.5°C
in 60 steps, each step was 10 s temperature. Expression
levels were calculated according to the ΔΔCt method
normalised to the Elval1 mRNA expression. The Elval1
g e n ew a su s e da sa ni n t e r n a ln o r m a l i s e r ,a si ts h o w e d
the least variation (basedo no u rm i c r o a r r a yd a t a )
among all different replicates and conditions.
RT-qPCR primers were designed at exon-exon bound-
aries using Primer 3 software [73], unless mentioned
otherwise (Additional file 6). The primers were initially
tested by running an end-point PCR for each using
SybrGreen master mix. The products were run on
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perform melting curve analysis.
Animal husbandry
Animals were bred in-house and food and water pro-
vided ad libitum. They were maintained, and experimen-
tation conducted under statutory Home Office
recommendation, regulatory, ethical and licensing pro-
cedures and under the Animals (Scientific Procedures)
Act 1986 (PPL 70/6160).
Additional file 1: A table listing genes initially prepared from genes
changing by dystrophin deficiency.
Additional file 2: A table listing all genes changing by dystrophin
deficiency that was used for further GO and IPA analyses.
Additional file 3: A table listing changing genes common to
“dystrophin siRNA treated versus untreated samples” and “GL2
siRNA treated versus untreated samples” comparisons.
Additional file 4: A table listing enriched GO terms amongst genes
changing by dystrophin deficiency.
Additional file 5: A table listing predicted networks by IPA to be
dysregulated by dystrophin deficiency.
Additional file 6: A table listing primers used for RT-qPCR.
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